- cafead   Jun 30, 2024 at 10:02: PM
via
article source
- Altimmune's anti-obesity therapy has a key feature that Wegovy doesn't.
- That means it could one day steal market share.
- Altimmune also has enough resources to clarify whether its candidate is a winner.
article source